The Incidence of Clostridioides difficile Infection in the Post-COVID-19 Era in a Hospital in Northern Greece
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Clarke, L.M.; Allegretti, J.R. The epidemiology and management of Clostridioides difficile infection—A clinical update. Aliment. Pharmacol. Ther. 2024. online ahead of print. [Google Scholar] [CrossRef] [PubMed]
- Drewes, J.L.; Chen, J.; Markham, N.O.; Knippel, R.J.; Domingue, J.C.; Tam, A.J.; Chan, J.L.; Kim, L.; McMann, M.; Stevens, C.; et al. Human Colon Cancer-Derived Clostridioides difficile Strains Drive Colonic Tumorigenesis in Mice. Cancer Discov. 2022, 12, 1873–1885. [Google Scholar] [CrossRef] [PubMed]
- Clements, A.C.A.; Magalhães, R.J.; Tatem, A.J.; Paterson, D.L.; Riley, T.V. Clostridium difficile PCR ribotype 027: Assessing the risks of further worldwide spread. Lancet Infect. Dis. 2010, 10, 395–404. [Google Scholar] [CrossRef] [PubMed]
- Davies, K.; Lawrence, J.; Berry, C.; Davis, G.; Yu, H.; Cai, B.; Gonzalez, E.; Prantner, I.; Kurcz, A.; Macovei, I.; et al. Risk factors for primary Clostridium difficile infection; results from the Observational Study of Risk Factors for Clostridium difficile Infection in Hospitalized Patients With Infective Diarrhea (ORCHID). Front. Public Health 2020, 8, 293. [Google Scholar] [CrossRef] [PubMed]
- Freeman, J.; Wilcox, M.H. Antibiotics and Clostridium difficile. Microbes Infect. 1999, 1, 377–384. [Google Scholar] [CrossRef]
- Health Protection Surveillance Centre (HPSC). Case Definitions for C. difficile Enhanced Surveillance; HPSC: Dublin, Ireland, 2014; Available online: https://www.hpsc.ie/a-z/microbiologyantimicrobialresistance/clostridioidesdifficile/enhancedsurveillance/ (accessed on 15 July 2024).
- Fu, Y.; Luo, Y.; Grinspan, A.M. Epidemiology of community-acquired and recurrent Clostridioides difficile infection. Ther. Adv. Gastroenterol. 2021, 14, 17562848211016248. [Google Scholar] [CrossRef]
- ECDC. Clostridioides (Clostridium) difficile Infections—Annual Epidemiological Report for 2016–2017; ECDC: Solna, Sweden, 2024. [Google Scholar]
- Guh, A.Y.; Mu, Y.; Winston, L.G.; Johnston, H.; Olson, D.; Farley, M.M.; Wilson, L.E.; Holzbauer, S.M.; Phipps, E.C.; Dumyati, G.K.; et al. Emerging Infections Program Clostridioides difficile Infection Working Group* Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. N. Engl. J. Med. 2020, 382, 1320–1330. [Google Scholar] [CrossRef]
- Samonis, G.; Vardakas, K.Z.; Tansarli, G.S.; Dimopoulou, D.; Papadimitriou, G.; Kofteridis, D.P.; Maraki, S.; Karanika, M.; Falagas, M.E. Clostridium difficile in Crete, Greece: Epidemiology, microbiology and clinical disease. Epidemiol. Infect. 2016, 144, 161–170. [Google Scholar] [CrossRef]
- Seugendo, M.; Janssen, I.; Lang, V.; Hasibuan, I.; Bohne, W.; Cooper, P.; Daniel, R.; Gunka, K.; Kusumawati, R.L.; Mshana, S.E.; et al. Prevalence and Strain Characterization of Clostridioides (Clostridium) difficile in Representative Regions of Germany, Ghana, Tanzania and Indonesia—A Comparative Multi-Center Cross-Sectional Study. Front. Microbiol. 2018, 9, 1843. [Google Scholar] [CrossRef]
- Rizzardi, K.; Norén, T.; Aspevall, O.; Mäkitalo, B.; Toepfer, M.; Johansson, Å.; Åkerlund, T. National surveillance for Clostridioides difficile infection, Sweden, 2009–2016. Emerg. Infect. Dis. 2018, 24, 1617–1625. [Google Scholar] [CrossRef]
- Ofori, E.; Ramai, D.; Dhawan, M.; Mustafa, F.; Gasperino, J.; Reddy, M. Community-acquired Clostridium difficile: Epidemiology, ribotype, risk factors, hospital and intensive care unit outcomes, and current and emerging therapies. J. Hosp. Infect. 2018, 99, 436–442. [Google Scholar] [CrossRef]
- Vehreschild, M.J.; Schreiber, S.; Von Müller, L.; Epple, H.J.; Weinke, T.; Manthey, C.; Oh, J.; Wahler, S.; Stallmach, A. Trends in the epidemiology of Clostridioides difficile infection in Germany. Infection 2023, 51, 1695–1702. [Google Scholar] [CrossRef] [PubMed]
- Karampatakis, T.; Tsergouli, K.; Kandilioti, E.; Nikopoulou, A.; Katsifa, H.; Kachrimanidou, M. Implication of COVID-19 pandemic on the incidence of Clostridioides difficile infection in a Greek tertiary hospital. J. Med. Microbiol. 2023, 72, 001689. [Google Scholar] [CrossRef]
- Curry, S. Clostridium difficile. Clin. Lab. Med. 2010, 30, 329–342. [Google Scholar] [CrossRef] [PubMed]
- Gateau, C.; Couturier, J.; Coia, J.; Barbut, F. How to: Diagnose infection caused by Clostridium difficile. Clin. Microbiol. Infect. 2018, 24, 463–468. [Google Scholar] [CrossRef]
- Gomez-Simmonds, A.; Kubin, C.J.; Yoko Furuya, E. Comparison of 3 severity criteria for Clostridium difficile infection. Infect. Control. Hosp. Epidemiol. 2014, 35, 196–199. [Google Scholar] [CrossRef] [PubMed]
- Kelly, C.R.; Fischer, M.; Allegretti, J.R.; LaPlante, K.; Stewart, D.B.; Limketkai, B.N.; Stollman, N.H. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am. J. Gastroenterol. 2021, 116, 1124–1147. [Google Scholar] [CrossRef]
- Wiegand, P.N.; Nathwani, D.; Wilcox, M.H.; Stephens, J.; Shelbaya, A.; Haider, S. Clinical and economic burden of Clostridium difficile infection in Europe: A systematic review of healthcare-facility-acquired infection. J. Hosp. Infect. 2012, 81, 1–14. [Google Scholar] [CrossRef] [PubMed]
- Sinnathamby, E.S.; Mason, J.W.; Flanagan, C.J.; Pearl, N.Z.; Burroughs, C.R.; De Witt, A.J.; Wenger, D.M.; Klapper, V.G.; Ahmadzadeh, S.; Varrassi, G.; et al. Clostridioides difficile Infection: A Clinical Review of Pathogenesis, Clinical Considerations, and Treatment Strategies. Cureus 2023, 15, e51167. [Google Scholar] [CrossRef]
- Popoff, M.R.; Bouvet, P. Clostridial toxins. Future Microbiol. 2009, 4, 1021–1064. [Google Scholar] [CrossRef]
- Buddle, J.E.; Fagan, R.P. Pathogenicity and virulence of Clostridioides difficile. Virulence 2023, 14, 2150452. [Google Scholar] [CrossRef]
- Kuehne, S.A.; Cartman, S.T.; Heap, J.T.; Kelly, M.L.; Cockayne, A.; Minton, N.P. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010, 467, 711–713. [Google Scholar] [CrossRef]
- Majumdar, A.; Govind, R. Regulation of Clostridioides difficile toxin production. Curr. Opin. Microbiol. 2022, 65, 95–100. [Google Scholar] [CrossRef] [PubMed]
- Gerding, D.N.; Johnson, S.; Rupnik, M.; Aktories, K. Clostridium difficile binary toxin CDT: Mechanism, epidemiology, and potential clinical importance. Gut Microbes 2014, 5, 15–27. [Google Scholar] [CrossRef] [PubMed]
- Bruxelle, J.F.; Mizrahi, A.; Hoÿs, S.; Collignon, A.; Janoir, C.; Péchiné, S. Clostridium difficile flagellin FliC: Evaluation as adjuvant and use in a mucosal vaccine against Clostridium difficile. PLoS ONE 2017, 12, e0187212. [Google Scholar] [CrossRef] [PubMed]
- Cymbal, M.; Chatterjee, A.; Baggott, B.; Auron, M. Management of Clostridioides difficile infection: Diagnosis, Treatment, and Future Perspectives. Am. J. Med. 2024, 137, 571–576. [Google Scholar] [CrossRef] [PubMed]
- Skoutelis, A.; Pefanis, A.; Tsiodras, S.; Sipsas, N.V.; Lelekis, M.; Lazanas, M.C.; Gargalianos, P.; Dalekos, G.N.; Roilides, E.; Samonis, G.; et al. Point-prevalence survey of healthcare facility-onset healthcare-associated Clostridium difficile infection in Greek hospitals outside the intensive care unit: The C. DEFINE study. PLoS ONE 2017, 12, e0182799. [Google Scholar] [CrossRef] [PubMed]
- Jachowicz, E.; Pobiega, M.; Różańska, A.; Wójkowska-Mach, J. Growing consumption of antibiotics and epidemiology of Clostridioides difficile infections in Poland: A need to develop new solutions. Acta Microbiol. Immunol. Hung. 2020, 67, 79–86. [Google Scholar] [CrossRef] [PubMed]
- Pickering, D.S.; Vernon, J.J.; Freeman, J.; Wilcox, M.H.; Chilton, C.H. Investigating the transient and persistent effects of heat on Clostridium difficile spores. J. Med. Microbiol. 2019, 68, 1445–1454. [Google Scholar] [CrossRef]
- Amodeo, D.; Manzi, P.; De Palma, I.; Puccio, A.; Nante, N.; Barcaccia, M.; Marini, D.; Pietrella, D. Efficacy of Violet-Blue (405 nm) LED Lamps for Disinfection of High-Environmental-Contact Surfaces in Healthcare Facilities: Leading to the Inactivation of Microorganisms and Reduction of MRSA Contamination. Pathogens 2023, 12, 1338. [Google Scholar] [CrossRef]
- Janoir, C. Virulence factors of Clostridium difficile and their role during infection. Anaerobe 2016, 37, 13–24. [Google Scholar] [CrossRef] [PubMed]
- Martin, J. The contribution of strains and hosts to outcomes in Clostridium difficile infection. Infect. Dis. Clin. N. Am. 2015, 29, 51–61. [Google Scholar] [CrossRef] [PubMed]
- Malyshev, D.; Jones, I.A.; McKracken, M.; Öberg, R.; Harper, G.M.; Joshi, L.T.; Andersson, M. Hypervirulent R20291 Clostridioides difficile spores show disinfection resilience to sodium hypochlorite despite structural changes. BMC Microbiol. 2023, 23, 59. [Google Scholar] [CrossRef]
- Liu, C.; Monaghan, T.; Yadegar, A.; Louie, T.; Kao, D. Insights into the Evolving Epidemiology of Clostridioides difficile Infection and Treatment: A Global Perspective. Antibiotics 2023, 12, 1141. [Google Scholar] [CrossRef] [PubMed]
Parameter | |
---|---|
Gender, male: n (%) | 42 (40.4) |
Age (years) (median, range) | 80.0 [18–97] |
Admission from home (n, %) | 84 (80.8) |
Recent admission (n, %) | 55 (52.9) |
Recent treatment with Abs (n, %) | 81 (77.9) |
Healthcare associated (healthcare facility-onset (HO) CDI and community-onset, healthcare facility-associated (CO-HCFA) CDI) (n, %) | 88 (84.6) |
Recurring infection (n, %) | 11 (10.6) |
No. of comorbidities (median, range) | 2.0 [0–4] |
Immunosuppression (n, %) | 31 (29.8) |
SARS-CoV-2 infection in the previous year (n, %) | 38 (36.5) |
Duration of admission prior to positive CDI test (median, range) | 4.0 [0–52] |
Severity of infection (severe; n, %) | 28 (26.9) |
Severity of infection (fulminant; n, %) | 22 (21.2) |
ICU admission (n, %) | 7 (6.7) |
Death 30 days (n, %) | 41 (39.4) |
Variable | Death | Recovery | p | 95% CI |
---|---|---|---|---|
Age (years; mean) | 76.61 | 74.97 | 0.588 | −7.948–2.031 |
Gender (male; %) | 41.5 | 39.7 | 0.856 | NA |
No. of comorbidities (mean) | 1.46 | 1.70 | 0.224 | −0.146–0.616 |
Days of hospitalization (days; mean) | 7.59 | 5.84 | 0.283 | −4.951–1.462 |
Healthcare-associated (yes; %) | 90.2 | 77.8 | 0.118 | NA |
Previous COVID-19 infection (yes; %) | 39.0 | 34.9 | 0.683 | NA |
Severity of infection (1—mild/moderate, 2—severe, 3—fulminant) (mean) | NA | NA | 0.000 | NA |
ICU admission (yes; %) | 17.1 | 0.0 | 0.001 | NA |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Terzaki, M.; Kouroupis, D.; Zarras, C.; Molyvas, D.; Michailidou, C.; Pateinakis, P.; Mpani, K.; Soukiouroglou, P.; Paida, E.; Simoulidou, E.; et al. The Incidence of Clostridioides difficile Infection in the Post-COVID-19 Era in a Hospital in Northern Greece. Diseases 2024, 12, 190. https://doi.org/10.3390/diseases12080190
Terzaki M, Kouroupis D, Zarras C, Molyvas D, Michailidou C, Pateinakis P, Mpani K, Soukiouroglou P, Paida E, Simoulidou E, et al. The Incidence of Clostridioides difficile Infection in the Post-COVID-19 Era in a Hospital in Northern Greece. Diseases. 2024; 12(8):190. https://doi.org/10.3390/diseases12080190
Chicago/Turabian StyleTerzaki, Maria, Dimitrios Kouroupis, Charalampos Zarras, Dimitrios Molyvas, Chrysi Michailidou, Panagiotis Pateinakis, Konstantina Mpani, Prodromos Soukiouroglou, Eleftheria Paida, Elisavet Simoulidou, and et al. 2024. "The Incidence of Clostridioides difficile Infection in the Post-COVID-19 Era in a Hospital in Northern Greece" Diseases 12, no. 8: 190. https://doi.org/10.3390/diseases12080190